在VEXAS综合征中应对治疗挑战:探索IL-6和JAK抑制剂在最前沿
Xiao Xiao Li1, Wen Hui Huang1, Xiao Bin Yang2
1Department of Rheumatology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
Molecular medicine (Cambridge, Mass.)
|September 17, 2024
概括
维克萨斯综合征是一种严重的自身免疫性疾病,由UBA1基因突变引起,具有不同的临床特征. 了解基因型-表型相关性对于量身定制治疗和改善VEXAS综合征患者的治疗结果至关重要.
科学领域:
- 自免疫性疾病 自免疫性疾病
- 遗传学 遗传学 是一个
- 临床医学 临床医学
背景情况:
- 维克萨斯综合征是一种严重的,不常见的自身免疫性疾病.
- 它的特征是UBA1基因的突变.
- 这种综合征呈现出一系列的临床表现.
研究的目的:
- 提供VEXAS综合征的全面概述,包括其发现,流行病学,遗传学和临床表现.
- 在VEXAS患者中研究不同基因型和不同临床表型之间的关系.
- 探索当前和未来的治疗策略,包括IL-6和JAK抑制剂.
主要方法:
- 文献综述和对VEXAS综合征现有研究的综合.
- 基因型-表型相关性的分析.
- 检查当前的治疗方案和新兴疗法.
主要成果:
- 维克萨斯综合征与特定的UBA1基因突变有关.
- 临床表现在患者之间可能有很大差异,可能与遗传特征相关.
- IL-6和JAK抑制剂显示出作为向治疗的前景.
结论:
- 基因型-表型相关性对于个性化治疗VEXAS综合征至关重要.
- 针对性治疗,如IL-6和JAK抑制剂提供了新的管理途径.
- 需要进一步的研究来充分阐明VEXAS综合征,并优化治疗策略.
相关概念视频
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Autoimmune Disorders
395
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
395
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119
T Cell Types and Functions
960
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
960


